Almac Discovery is a research driven drug discovery company with operations in Edinburgh (protein therapeutics), Manchester (bio-informatics) and the medical and life sciences campus at Queen’s University Belfast (medicinal chemistry and biology).
The company focusses on identifying novel, early stage drug discovery projects in areas of unmet medical need, exploiting both small molecule and protein-based approaches to discover targeted therapeutics. The convergence of small molecule drug discovery with protein engineering expertise offers the further potential to develop truly innovative new therapeutic approaches which bridge the two areas.
The combination of the highest quality science, dedicated, passionate people and access to a strong academic network positions Almac Discovery to succeed in the challenging world of modern drug discovery. We work creatively and energetically to translate early stage research from concept to therapeutic opportunity. Advancing human health requires exceptional people, and your talent, experience and passion will be critical in helping us to make a difference to the health and lives of patients.
Almac Discovery is a member of the Almac Group but is not a service provider. It follows a biotech business model that means it develops novel early stage projects to partner with pharmaceutical companies for further development. The Almac group is an exceptional, award winning, drug development solutions provider at the forefront of the pharmaceutical industry. The group is a privately owned organisation that has organically grown over 50 years now employing almost 5,000 highly skilled personnel worldwide. The Global headquarters is located in Craigavon, Northern Ireland with additional operations throughout Europe (UK, Ireland), across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Japan).